Obermatt

Niagen Bioscience

NAQ:NAGE · US1710774076
Life Sciences Tools & ServicesSmall

360

71
EV / EBIT42
Price / Owner Earnings40
Owner Earnings Yield76
Dividend Yield1
Price/Sales76
EV / Gross Profit49
Price/Book48
Return on Capital75
Cash Return on Capital88
Return on Equity90
EBIT Margin54
Gross Profitability87
Cash Conversion10
Accruals15
Owner Earnings Margin86
Sales growth66
Profit Growth43
Long-Term EPS Growth18
Owner Earnings Growth57
Reinvestment98
Price momentum5
Debt load100
Refinancing67
Debt Payback100
Liquidity20
Analyst ratings100
Opinion Changes50
Price Target Upside97
Market mood75
Value Creation14/20strong value creator
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

Niagen Bioscience generates returns well above its cost of capital, the foundation of durable shareholder value.

Profile

CountryUSA
IndustryLife Sciences Tools & Services
SizeSmall
TypePublic Company
ExchangeNASDAQCM
Employees127
ISINUS1710774076
Last UpdateApr 2, 2026
Themes
Health DiagnosticsNutraceuticalLifestyleBiotechnologyManufacturingProduct ResearchWellness

Description

Niagen Bioscience, Inc. operates as a global bioscience company. The company is dedicated to healthy aging. Consumer Products segment This segment provides finished dietary supplement products that contain the company's proprietary ingredients, com…

Analysis

Middle-of-the-road

Niagen Bioscience, Inc. sits in the middle of our grid: average quality, average price, no obvious signal in either direction. Worth noting: the cash the business generates has lagged behind what the income statement shows.

On valuation, the picture is attractive. The owner-earnings multiple stands at 14.2×; owner earnings: the cash an owner could take out each year.

Growth is moderate; the safety picture is sturdy. The company scores 14/20 on our value-creation score: strong value creator.

Flags to be aware of: Some accounting patterns deserve a closer look. Reported profits have run ahead of actual cash for several periods. As always: this describes the company's numbers; it is not a recommendation.

360° rank · history

1007550250
71
2023202420252026

All-time high

71

Mar 2026

All-time low

14

Jan 2024

Average rank

43

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
76
45
80
77
Price/Earnings
42
11
32
44
Price/Book
48
5
32
26
Dividend Yield
1
1
1
1
Value (overall)
51
10
45
45

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Niagen Bioscience with its peers
Bio-Rad Laboratories
NYQ:BIO
48
CountryUSA
IndustryLife Sciences Tools & Services
SizeLarge
Full Stock Analysis →
West Pharmaceutical Services
NYQ:WST
80
CountryUSA
IndustryLife Sciences Tools & Services
SizeLarge
Full Stock Analysis →
Avantor
NYQ:AVTR
13
CountryUSA
IndustryLife Sciences Tools & Services
SizeX-Large
Full Stock Analysis →
Bruker
NSQ:BRKR
41
CountryUSA
IndustryLife Sciences Tools & Services
SizeLarge
Full Stock Analysis →
Revvity
NYQ:RVTY
52
CountryUSA
IndustryLife Sciences Tools & Services
SizeLarge
Full Stock Analysis →
Lifecore Biomedical
NSQ:LFCR
12
CountryUSA
IndustryLife Sciences Tools & Services
SizeSmall
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →